Biodefense Headlines – October 1, 2017

October 1, 2017

See what we’re reading this week at Global Biodefense on topics including curbing the threat of MERS-CoV, BARDA medical countermeasure contracts, and a look at how the 1918 pandemic revolutionized public health. [Read more]

BARDA Backs Antibody Therapy Against MERS Virus

August 22, 2016

The Biomedical Advanced Research and Development Authority (BARDA) has awarded a contract to Regeneron Pharmaceuticals, Inc. to manufacture and study two antibody therapies for the potential prevention and treatment of Middle East [Read more]

Biodefense Headlines – August 21, 2016

August 21, 2016

See what we’re reading this week at Global Biodefense on topics including Ebola response lessons learned, conflicting studies on FluMist, and anthrax in Siberia. POLICY & POLICTICS UN makes first public admission of blame [Read more]

NIH Evaluating New Antibody Treatment for MERS-CoV

August 11, 2016

Phase I Clinical Trials are underway for SAB Biotherapeutics’ antibody treatment (SAB-301) for Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The study, sponsored and conducted by National Institutes of Health (NIH), will evaluate [Read more]

MERS-CoV Less Virulent During Outbreak?

March 7, 2016

A study published last week in mBio suggests that the Middle East Respiratory Syndrome coronavirus (MERS-CoV) develops mutations that make the virus less virulent during an outbreak rather than more virulent, having [Read more]

Biodefense Headlines – March 6, 2016

March 6, 2016

See what we’re reading this week at Global Biodefense on topics including Agroterrorism, preparedness for epidemics, and Lassa Fever in Nigeria. BIODEFENSE POLICY & PRACTICES Lawmakers assess US vulnerability to agroterrorist attack (HS Today) [Read more]

Biodefense Headlines – Feb 28, 2016

February 28, 2016

See what we’re reading this week at Global Biodefense on topics including Zika diagnostics, CDC’s field epidemiology officers, and biosecurity in Iraq. BIODEFENSE POLICY & PRACTICES Improving the recommendations of the Blue Ribbon Biodefense [Read more]

1 2 3 9